Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: amantadine hydrochloride Clear all

Conditions: Tobacco Use Disorder
Interventions: Memantine, bupropion, placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Memantine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Alzheimer's Disease
Interventions: Memantine, Placebo; Drug
Lead sponsor: Florida Atlantic University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Schizophrenia
Interventions: memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: National City, California • San Diego, California • Miami, Florida + 10 more

Conditions: Depressive Disorder
Interventions: memantine, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cocaine-Related Disorders
Interventions: Propranolol, Amantadine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
Interventions: Memantine, Placebo, Cognitive Assessment; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Walking Impairment, Multiple Sclerosis
Interventions: ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo; Drug · Other
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 78
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more

Conditions: Multiple Sclerosis
Interventions: placebo, memantine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lupus Erythematosus, Systemic
Interventions: Memantine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Alzheimer Disease
Interventions: memantine; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Chorea, Huntington's Disease
Interventions: Amantadine; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 72
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: Autism, Pediatric Autism
Interventions: Memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more

Conditions: Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: Traumatic Brain Injury
Interventions: Memantine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar Disorder
Interventions: Memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more

Conditions: Autism, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions: memantine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Memantine, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions: Olanzapine, Amantadine, Olanzapine and placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Stroke, Ischemic, Stroke Hemorrhagic
Interventions: Amantadine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Binge Eating Disorder
Interventions: memantine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 16 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl), Placebo capsules; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 64
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Search by objective public record fields.

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

Memantine Augmentation of Antidepressants

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Memantine for Spasticity in MS Patients

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

Treatment of Huntington's Chorea With Amantadine

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

Memantine in Adult Autism Spectrum Disorder

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

Promoting Recovery After STroke With Amantadine

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine